Showing results for "Checkpoint" in Physical Illness & Disease
1 result
-
-
Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs)
- Written by: Annenberg Center for Health Sciences
- Original Recording
-
Overall0
-
Performance0
-
Story0
Immune checkpoint inhibitors (ICIs) have transformed oncology but IV administration can cause infusion reactions, require line access, and add staff and chair-time burden. Recently, atezolizumab and nivolumab were approved for subcutaneous use, with more in development. In this podcast, oncologists Lucio Gordan, MD, and Saby George, MD, discuss the burden of IV ICIs, how subcutaneous options address these issues, compare efficacy and safety, and highlight the role of multidisciplinary teams in treatment decisions and workflow optimization.
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.Add to cart failed.
Please try again laterAdd to wishlist failed.
Please try again laterRemove from wishlist failed.
Please try again laterFollow podcast failed
Unfollow podcast failed
-